TW202419103A - 用於治療類風濕性關節炎之組成物及方法 - Google Patents

用於治療類風濕性關節炎之組成物及方法 Download PDF

Info

Publication number
TW202419103A
TW202419103A TW112135625A TW112135625A TW202419103A TW 202419103 A TW202419103 A TW 202419103A TW 112135625 A TW112135625 A TW 112135625A TW 112135625 A TW112135625 A TW 112135625A TW 202419103 A TW202419103 A TW 202419103A
Authority
TW
Taiwan
Prior art keywords
antibody
individual
weeks
rheumatoid arthritis
score
Prior art date
Application number
TW112135625A
Other languages
English (en)
Chinese (zh)
Inventor
迪波拉 包爾
亞歷山大 勃狄
尼爾 格林漢
永 林
賈尼 帕里諾
拉胡 帕特爾
珍奈特 汎阿德勒斯伯格
胡貝特 汎霍赫斯特拉騰
Original Assignee
法商賽諾菲生物技術公司
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by 法商賽諾菲生物技術公司, 美商再生元醫藥公司 filed Critical 法商賽諾菲生物技術公司
Publication of TW202419103A publication Critical patent/TW202419103A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112135625A 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法 TW202419103A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16305253.3 2016-03-07
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664.3 2016-05-20
EP16170664 2016-05-20
EP16306111.2 2016-09-05
EP16306111 2016-09-05

Publications (1)

Publication Number Publication Date
TW202419103A true TW202419103A (zh) 2024-05-16

Family

ID=58387910

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112135625A TW202419103A (zh) 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法
TW110146922A TWI819435B (zh) 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法
TW106107363A TWI747885B (zh) 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110146922A TWI819435B (zh) 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法
TW106107363A TWI747885B (zh) 2016-03-07 2017-03-07 用於治療類風濕性關節炎之組成物及方法

Country Status (18)

Country Link
US (1) US20190100585A1 (https=)
EP (1) EP3426295A1 (https=)
JP (2) JP7166925B2 (https=)
KR (3) KR20260049875A (https=)
CN (1) CN109069642A (https=)
AU (2) AU2017229364A1 (https=)
BR (1) BR112018067851A2 (https=)
CA (1) CA3016880A1 (https=)
CL (1) CL2018002559A1 (https=)
CR (1) CR20180465A (https=)
EA (1) EA201892005A1 (https=)
IL (2) IL261515B2 (https=)
MX (2) MX2018010815A (https=)
PH (1) PH12018501894A1 (https=)
SG (2) SG10202012182YA (https=)
TN (1) TN2018000312A1 (https=)
TW (3) TW202419103A (https=)
WO (1) WO2017155990A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
SG11202101674QA (en) * 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) * 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
MX377190B (es) * 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Also Published As

Publication number Publication date
CA3016880A1 (en) 2017-09-14
TWI747885B (zh) 2021-12-01
TW201808993A (zh) 2018-03-16
SG10202012182YA (en) 2021-01-28
JP2023011711A (ja) 2023-01-24
JP7745529B2 (ja) 2025-09-29
SG11201807614SA (en) 2018-10-30
MX2023014841A (es) 2024-01-15
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
TWI819435B (zh) 2023-10-21
US20190100585A1 (en) 2019-04-04
KR20260049875A (ko) 2026-04-14
TW202239767A (zh) 2022-10-16
JP7166925B2 (ja) 2022-11-08
CN109069642A (zh) 2018-12-21
EA201892005A1 (ru) 2019-02-28
EP3426295A1 (en) 2019-01-16
IL261515A (en) 2018-10-31
IL308539A (en) 2024-01-01
CR20180465A (es) 2019-03-04
TN2018000312A1 (en) 2020-01-16
MX2018010815A (es) 2019-01-10
NZ746988A (en) 2023-10-27
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
JP2019507775A (ja) 2019-03-22
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
KR20180114955A (ko) 2018-10-19
AU2024203011A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
JP2018512435A (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
US20230127528A1 (en) Compositions and methods for treating juvenile idiopathic arthritis
US11472870B2 (en) Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
JP7841752B2 (ja) 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法
AU2017366870B2 (en) A pharmaceutical composition for averting opioid addiction
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same